Logo image of ZLAB

ZAI LAB LTD-ADR (ZLAB) Stock Overview

USA - NASDAQ:ZLAB - US98887Q1040 - ADR

28.74 USD
+0.45 (+1.59%)
Last: 10/20/2025, 8:23:14 PM
28.9001 USD
+0.16 (+0.56%)
After Hours: 10/20/2025, 8:23:14 PM

ZLAB Key Statistics, Chart & Performance

Key Statistics
Market Cap3.20B
Revenue(TTM)427.80M
Net Income(TTM)-212520000
Shares111.27M
Float102.79M
52 Week High44.34
52 Week Low23.82
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.96
PEN/A
Fwd PE65.26
Earnings (Next)11-11 2025-11-11
IPO2020-09-28
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


ZLAB short term performance overview.The bars show the price performance of ZLAB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -5 -10 -15 -20

ZLAB long term performance overview.The bars show the price performance of ZLAB in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20

The current stock price of ZLAB is 28.74 USD. In the past month the price decreased by -13.3%. In the past year, price decreased by -11.21%.

ZAI LAB LTD-ADR / ZLAB Daily stock chart

ZLAB Latest News, Press Relases and Analysis

ZLAB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.91 409.95B
AMGN AMGEN INC 13.91 163.30B
GILD GILEAD SCIENCES INC 15.91 152.76B
VRTX VERTEX PHARMACEUTICALS INC 24.74 107.45B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 64.39B
REGN REGENERON PHARMACEUTICALS 12.64 61.13B
ARGX ARGENX SE - ADR 92.23 52.30B
INSM INSMED INC N/A 35.49B
ONC BEONE MEDICINES LTD-ADR 5.15 34.99B
BNTX BIONTECH SE-ADR N/A 25.95B
NTRA NATERA INC N/A 25.89B
BIIB BIOGEN INC 9.16 21.50B

About ZLAB

Company Profile

ZLAB logo image Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is committed to addressing the unmet medical needs in the fields of tumors, autoimmune diseases, infectious diseases and central nervous system diseases through product discovery, development and commercialization. The firm has a series of patented drug candidates from the discovery stage to the late clinical project. These include ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others.

Company Info

ZAI LAB LTD-ADR

Building B, 899 Halei Road, Pudong

Shanghai SHANGHAI 201210 CN

CEO: Samantha (Ying) Du

Employees: 1869

ZLAB Company Website

ZLAB Investor Relations

Phone: 862161632588

ZAI LAB LTD-ADR / ZLAB FAQ

What is the stock price of ZAI LAB LTD-ADR today?

The current stock price of ZLAB is 28.74 USD. The price increased by 1.59% in the last trading session.


What is the ticker symbol for ZAI LAB LTD-ADR stock?

The exchange symbol of ZAI LAB LTD-ADR is ZLAB and it is listed on the Nasdaq exchange.


On which exchange is ZLAB stock listed?

ZLAB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ZAI LAB LTD-ADR stock?

13 analysts have analysed ZLAB and the average price target is 33.97 USD. This implies a price increase of 18.21% is expected in the next year compared to the current price of 28.74. Check the ZAI LAB LTD-ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ZAI LAB LTD-ADR worth?

ZAI LAB LTD-ADR (ZLAB) has a market capitalization of 3.20B USD. This makes ZLAB a Mid Cap stock.


How many employees does ZAI LAB LTD-ADR have?

ZAI LAB LTD-ADR (ZLAB) currently has 1869 employees.


What are the support and resistance levels for ZAI LAB LTD-ADR (ZLAB) stock?

ZAI LAB LTD-ADR (ZLAB) has a support level at 28.29 and a resistance level at 32.39. Check the full technical report for a detailed analysis of ZLAB support and resistance levels.


Is ZAI LAB LTD-ADR (ZLAB) expected to grow?

The Revenue of ZAI LAB LTD-ADR (ZLAB) is expected to grow by 43.01% in the next year. Check the estimates tab for more information on the ZLAB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ZAI LAB LTD-ADR (ZLAB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ZAI LAB LTD-ADR (ZLAB) stock pay dividends?

ZLAB does not pay a dividend.


When does ZAI LAB LTD-ADR (ZLAB) report earnings?

ZAI LAB LTD-ADR (ZLAB) will report earnings on 2025-11-11.


What is the Price/Earnings (PE) ratio of ZAI LAB LTD-ADR (ZLAB)?

ZAI LAB LTD-ADR (ZLAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.96).


What is the Short Interest ratio of ZAI LAB LTD-ADR (ZLAB) stock?

The outstanding short interest for ZAI LAB LTD-ADR (ZLAB) is 4.74% of its float. Check the ownership tab for more information on the ZLAB short interest.


ZLAB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ZLAB Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to ZLAB. Both the profitability and financial health of ZLAB have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ZLAB Financial Highlights

Over the last trailing twelve months ZLAB reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS increased by 33.33% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -18.26%
ROE -26.84%
Debt/Equity 0.22
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%9.43%
EPS 1Y (TTM)33.33%
Revenue 1Y (TTM)32.56%

ZLAB Forecast & Estimates

13 analysts have analysed ZLAB and the average price target is 33.97 USD. This implies a price increase of 18.21% is expected in the next year compared to the current price of 28.74.

For the next year, analysts expect an EPS growth of 42.88% and a revenue growth 43.01% for ZLAB


Analysts
Analysts78.46
Price Target33.97 (18.2%)
EPS Next Y42.88%
Revenue Next Year43.01%

ZLAB Ownership

Ownership
Inst Owners31.3%
Ins Owners1.73%
Short Float %4.74%
Short Ratio6.6